Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['nivo', 'triplet,(-triplete)', 'ipi+']
until we have os results, positive dfs alone is not a surprise since a third active drug was added. only if the dfs of the triplet is better than ipi+nivo followed by cabo, it would be a meaningful result and only if significant enough it maybe worth the added toxicity #esmo22 
GU oncologist @RabinMedical_  #prostatecancer #bladdercancer #kidneycancer #testicularcancer